GLP-1这次真的“卷到头了”

药渡
16 Jul

全球超过30亿超重或肥胖人群构成的庞大市场,让GLP-1类药物成为医药行业最炙手可热的赛道。然而刚落幕的美国糖尿病协会年会(ADA 2025)上,各大药企亮虽然纷纷亮出了自己的家底,却仍然抵不住一个显而易见的事实:GLP-1的时代的故事好像正在走向结尾。MNC竞速时刻MNC在GLP-1减重降糖领域的布局呈现加速态势,核心策略正围绕着技术迭代、靶点创新和全球化合作展开。诺和诺德(Novo ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10